Table 1 Demographic and clinical factors across rs1501357 genotypes for study 1.

From: Evidence for the contribution of HCN1 gene polymorphism (rs1501357) to working memory at both behavioral and neural levels in schizophrenia patients and healthy controls

 

Mean ± SD

F or χ2

P

TT

TC

CC

Age

     

 Controls

26.73 ± 8.22

26.40 ± 8.18

25.53 ± 8.26

1.297

0.274

 Patients

28.77 ± 7.73

28.40 ± 7.89

29.60 ± 7.79

1.705

0.182

Gender (male/female)

     

 Controls

100/83

208/226

119/106

3.138

0.208

 Patients

129/78

284/169

138/78

0.129

0.938

Education (years)

     

 Controls

9.28 ± 3.37

9.43 ± 3.51

9.80 ± 3.13

1.408

0.245

 Patients

9.94 ± 3.18

9.76 ± 3.10

9.12 ± 3.04

2.893

0.056

PANSS positive

     

 Patients

18.92 ± 6.87

18.33 ± 7.04

18.57 ± 7.11

0.296

0.744

PANSS negative

     

 Patients

17.27 ± 7.88

17.39 ± 7.94

17.81 ± 8.21

0.170

0.844

Medication dose (mg/day)a

     

 Patients

599.28 ± 381.64

651.90 ± 521.45

623.40 ± 437.92

0.743

0.476

  1. aChlorpromazine equivalents.
Back to article page